IDO1 and neoplasm: Since the enzymatic activity of IDO1 and TDO2 have been shown to contribute to the immune-suppressive condition in the tumor microenvironment (reviewed in9), small molecule inhibitors are regarded as a therapeutic option to reinvigorate anti-tumor immunity.